Timed alternate administration of decitabine and 5-azacytidine for cancer treatment
AssigneeThe Cleveland Clinic Foundation
InventorsYogen Saunthararajah, Vamsidhar Velcheti, Kai Kang, Xiaorong Gu, Rita Tohme
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Cleveland Clinic Foundation
InventorsYogen Saunthararajah, Vamsidhar Velcheti, Kai Kang, Xiaorong Gu, Rita Tohme
Estimating the term…
Provided herein are compositions, systems, kits, and methods for treating a patient with cancer by alternate administration of decitabine and 5-azacytidine, or administration of decitabine two times per week on consecutive days, which is generally timed to bypass auto-dampening and exploit cross-priming. Such administration is combined with an inhibitor of the enzyme cytidine deaminase (e.g., tetrahydrouridine) that otherwise rapidly catabolizes decitabine and 5-azacytidine. In certain embodiments, the time between cycles of decitabine and 5-azacytidine administration is about three to four days or five to ten days.
A method of treating a human subject with cancer comprising, or consisting essentially of:
A method of treating a human subject with cancer comprising, or consisting essentially of:
Dependencies are inferred from the claim text.